NASDAQ:FLGT Fulgent Genetics (FLGT) Stock Forecast, Price & News $38.04 -1.59 (-4.01%) (As of 06/9/2023 ET) Add Compare Share Share Today's Range$37.92▼$39.6350-Day Range$28.52▼$40.7052-Week Range$28.27▼$65.17Volume248,471 shsAverage Volume232,754 shsMarket Capitalization$1.13 billionP/E RatioN/ADividend YieldN/APrice Target$42.33 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial MediaSustainabilityProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial MediaSustainability Fulgent Genetics MarketRank™ ForecastAnalyst RatingModerate Buy2.67 Rating ScoreUpside/Downside11.3% Upside$42.33 Price TargetShort InterestHealthy4.08% of Float Sold ShortDividend StrengthN/ASustainability-0.67Upright™ Environmental ScoreNews Sentiment0.32Based on 11 Articles This WeekInsider TradingSelling Shares$154,591 Sold Last QuarterProj. Earnings GrowthGrowingFrom ($2.23) to ($1.80) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.23 out of 5 starsMedical Sector289th out of 987 stocksMedical Laboratories Industry7th out of 22 stocks 2.3 Analyst's Opinion Consensus RatingFulgent Genetics has received a consensus rating of Buy. The company's average rating score is 2.67, and is based on 2 buy ratings, 1 hold rating, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $42.33, Fulgent Genetics has a forecasted upside of 11.3% from its current price of $38.04.Amount of Analyst CoverageFulgent Genetics has received no research coverage in the past 90 days. Previous Next 3.0 Short Interest Percentage of Shares Shorted4.08% of the float of Fulgent Genetics has been sold short.Short Interest Ratio / Days to CoverFulgent Genetics has a short interest ratio ("days to cover") of 3.5, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Fulgent Genetics has recently increased by 7.32%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldFulgent Genetics does not currently pay a dividend.Dividend GrowthFulgent Genetics does not have a long track record of dividend growth. Previous Next 4.1 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreFulgent Genetics has received a 58.06% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is false driven by its "Private genetic testing services", "Private infectious disease diagnostics services", and "Private medical laboratory services" products. See details.Environmental SustainabilityThe Environmental Impact score for Fulgent Genetics is -0.67. Previous Next 2.4 News and Social Media Coverage News SentimentFulgent Genetics has a news sentiment score of 0.32. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.74 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 11 news articles for Fulgent Genetics this week, compared to 3 articles on an average week.Search InterestOnly 12 people have searched for FLGT on MarketBeat in the last 30 days. This is a decrease of -57% compared to the previous 30 days.MarketBeat Follows8 people have added Fulgent Genetics to their MarketBeat watchlist in the last 30 days. This is an increase of 700% compared to the previous 30 days. Previous Next 3.3 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Fulgent Genetics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $154,591.00 in company stock.Percentage Held by Insiders31.76% of the stock of Fulgent Genetics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions43.22% of the stock of Fulgent Genetics is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 1.3 Earnings and Valuation Earnings GrowthEarnings for Fulgent Genetics are expected to grow in the coming year, from ($2.23) to ($1.80) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Fulgent Genetics is -42.74, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Fulgent Genetics is -42.74, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioFulgent Genetics has a P/B Ratio of 0.88. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Fulgent Genetics (NASDAQ:FLGT) StockFulgent Genetics, Inc. is a technology company, which engages in the provision of gene testing and sequencing solutions. It offers genes and panels, known mutation, hereditary cancer, carrier screening, and tumor profiling solutions. The company was founded by Ming Hsieh on May 13, 2016 and is headquartered in El Monte, CA.Read More Receive FLGT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Fulgent Genetics and its competitors with MarketBeat's FREE daily newsletter. Email Address FLGT Stock News HeadlinesJune 8, 2023 | americanbankingnews.comPaul Kim Sells 1,403 Shares of Fulgent Genetics, Inc. (NASDAQ:FLGT) StockJune 7, 2023 | americanbankingnews.comFulgent Genetics, Inc. (NASDAQ:FLGT) COO Jian Xie Sells 1,433 Shares of StockJune 10, 2023 | Behind the Markets (Ad)The single greatest medical breakthrough of all time?We are on the cusp of a medical breakthrough. And soon, this single breakthrough could lead to the cure of over 6,000 genetic diseases, including Alzheimer's, heart disease, and even cancer! This reminds me of Amgen, where early investors made as much as 46,751% when they released their revolutionary drug to the market.June 7, 2023 | americanbankingnews.comFulgent Genetics, Inc. (NASDAQ:FLGT) Insider Hanlin Gao Sells 1,000 SharesJune 6, 2023 | finance.yahoo.comGot $2,500? This Dirt Cheap Growth Stock Could Be Worth Buying Hand Over FistJune 5, 2023 | finance.yahoo.comFulgent Data at ASCO 2023 Highlights Progress for Its Lead Therapeutic Oncology Candidate, FID-007, in Various CancersMay 30, 2023 | americanbankingnews.comFulgent Genetics, Inc. (NASDAQ:FLGT) Short Interest Up 7.3% in MayMay 23, 2023 | finance.yahoo.com2 Undervalued Stocks to Buy for Potentially Massive Gains in the Next 10 YearsJune 10, 2023 | Behind the Markets (Ad)BREAKING: Tiny biotech successfully treats blindnessThere's a tiny biotech in Cambridge that's using a breakthrough technology to treat blindness. This company has already shown success in human trials... And Our research shows that anyone who gets in today could see a 46,751% return.May 23, 2023 | finance.yahoo.comBetter Diversified Biotech Stock: 23andMe vs. Fulgent GeneticsMay 21, 2023 | americanbankingnews.comFulgent Genetics (NASDAQ:FLGT) Research Coverage Started at StockNews.comMay 19, 2023 | msn.comFulgent Genetics Earnings Perspective: Return On Capital EmployedMay 18, 2023 | finance.yahoo.comFulgent Announces Upcoming Presentation of Clinical Data for Its Lead Therapeutic Oncology Candidate, FID-007, at ASCO 2023 Annual MeetingMay 14, 2023 | msn.comWhat To Expect From Fulgent Genetics In 2023May 10, 2023 | americanbankingnews.comFulgent Genetics (NASDAQ:FLGT) Releases FY 2023 Earnings GuidanceMay 9, 2023 | americanbankingnews.comFulgent Genetics (NASDAQ:FLGT) PT Raised to $37.00May 8, 2023 | finance.yahoo.com3 Cash-Rich Biotechs in a Market That's Tough on the Debt BurdenedMay 8, 2023 | americanbankingnews.comFulgent Genetics (NASDAQ:FLGT) Releases FY23 Earnings GuidanceMay 5, 2023 | finance.yahoo.comFulgent Genetics, Inc. (FLGT) Reports Q1 Loss, Tops Revenue EstimatesMay 5, 2023 | finance.yahoo.comFulgent Reports First Quarter 2023 Financial ResultsMay 4, 2023 | msn.comFulgent Genetics Q1 2023 Earnings PreviewMay 4, 2023 | msn.comPreview: Fulgent Genetics's EarningsMay 4, 2023 | americanbankingnews.comFulgent Genetics (FLGT) Scheduled to Post Earnings on FridayApril 20, 2023 | finance.yahoo.comFulgent Genetics to Announce First Quarter 2023 Financial Results on Friday May 5, 2023April 18, 2023 | morningstar.comFulgent Genetics Inc FLGT Stock QuoteApril 14, 2023 | finance.yahoo.comReturns Are Gaining Momentum At Fulgent Genetics (NASDAQ:FLGT)April 12, 2023 | msn.comAre Medical Stocks Lagging Fulgent Genetics (FLGT) This Year?See More Headlines FLGT Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart FLGT Company Calendar Last Earnings5/05/2023Today6/09/2023Next Earnings (Estimated)8/03/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Medical laboratories Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:FLGT CUSIPN/A CIK1674930 Webwww.fulgentgenetics.com Phone(626) 350-0537Fax626-454-1667Employees1,012Year Founded2011Price Target and Rating Average Stock Price Forecast$42.33 High Stock Price Forecast$45.00 Low Stock Price Forecast$37.00 Forecasted Upside/Downside+11.3%Consensus RatingModerate Buy Rating Score (0-4)2.67 Research Coverage3 Analysts Profitability EPS (Most Recent Fiscal Year)($0.89) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$143.40 million Net Margins-7.10% Pretax Margin-10.69% Return on Equity-1.05% Return on Assets-0.96% Debt Debt-to-Equity RatioN/A Current Ratio7.09 Quick Ratio7.09 Sales & Book Value Annual Sales$618.97 million Price / Sales1.83 Cash Flow$6.26 per share Price / Cash Flow6.08 Book Value$43.14 per share Price / Book0.88Miscellaneous Outstanding Shares29,700,000Free Float20,268,000Market Cap$1.13 billion OptionableNot Optionable Beta1.55 Social Links Key ExecutivesMing HsiehChairman & Chief Executive OfficerJames XiePresident & Chief Operating OfficerPaul H. KimChief Financial OfficerHarry GaoChief Scientific Officer & Laboratory DirectorLawrence M. WeissChief Medical OfficerKey CompetitorsViridian TherapeuticsNASDAQ:VRDNProgenityNASDAQ:PROGRadNetNASDAQ:RDNTVeracyteNASDAQ:VCYTCareDxNASDAQ:CDNAView All CompetitorsInsiders & InstitutionsAurora Investment CounselSold 1,370 shares on 6/6/2023Ownership: 0.033%Aurora Investment CounselSold 10,807 shares on 6/5/2023Ownership: 0.001%Hanlin GaoSold 1,000 sharesTotal: $40,300.00 ($40.30/share)Jian XieSold 1,433 sharesTotal: $57,749.90 ($40.30/share)Paul KimSold 1,403 sharesTotal: $56,540.90 ($40.30/share)View All Insider TransactionsView All Institutional Transactions FLGT Stock - Frequently Asked Questions Should I buy or sell Fulgent Genetics stock right now? 3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Fulgent Genetics in the last year. There are currently 1 hold rating and 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" FLGT shares. View FLGT analyst ratings or view top-rated stocks. What is Fulgent Genetics' stock price forecast for 2023? 3 brokers have issued 1 year target prices for Fulgent Genetics' shares. Their FLGT share price forecasts range from $37.00 to $45.00. On average, they anticipate the company's stock price to reach $42.33 in the next twelve months. This suggests a possible upside of 11.3% from the stock's current price. View analysts price targets for FLGT or view top-rated stocks among Wall Street analysts. How have FLGT shares performed in 2023? Fulgent Genetics' stock was trading at $29.78 on January 1st, 2023. Since then, FLGT shares have increased by 27.7% and is now trading at $38.04. View the best growth stocks for 2023 here. When is Fulgent Genetics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, August 3rd 2023. View our FLGT earnings forecast. How were Fulgent Genetics' earnings last quarter? Fulgent Genetics, Inc. (NASDAQ:FLGT) posted its quarterly earnings results on Friday, May, 5th. The company reported ($0.47) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.68) by $0.21. The company earned $66.17 million during the quarter, compared to analysts' expectations of $61.95 million. Fulgent Genetics had a negative trailing twelve-month return on equity of 1.05% and a negative net margin of 7.10%. What ETFs hold Fulgent Genetics' stock? ETFs with the largest weight of Fulgent Genetics (NASDAQ:FLGT) stock in their portfolio include Invesco Dynamic Biotechnology & Genome ETF (PBE), ETFMG Treatments Testing and Advancements ETF (GERM), ROBO Global Healthcare Technology and Innovation ETF (HTEC), SPDR S&P Health Care Services ETF (XHS), Janus Henderson Small Cap Growth Alpha ETF (JSML), Global X Genomics & Biotechnology ETF (GNOM), Invesco S&P SmallCap Health Care ETF (PSCH) and WisdomTree U.S. SmallCap Fund (EES). What guidance has Fulgent Genetics issued on next quarter's earnings? Fulgent Genetics issued an update on its second quarter 2023 earnings guidance on Sunday, May, 7th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $62.00 million-$62.00 million, compared to the consensus revenue estimate of $60.31 million. What other stocks do shareholders of Fulgent Genetics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Fulgent Genetics investors own include NVIDIA (NVDA), CRISPR Therapeutics (CRSP), Inseego (INSG), NeoGenomics (NEO), Invitae (NVTA), Block (SQ), JD.com (JD), Marvell Technology (MRVL), Teladoc Health (TDOC) and Editas Medicine (EDIT). When did Fulgent Genetics IPO? (FLGT) raised $60 million in an IPO on Thursday, September 29th 2016. The company issued 4,600,000 shares at $12.00-$14.00 per share. Credit Suisse and Piper Jaffray served as the underwriters for the IPO and Raymond James and BTIG were co-managers. What is Fulgent Genetics' stock symbol? Fulgent Genetics trades on the NASDAQ under the ticker symbol "FLGT." Who are Fulgent Genetics' major shareholders? Fulgent Genetics' stock is owned by many different institutional and retail investors. Top institutional shareholders include BlackRock Inc. (12.28%), Dimensional Fund Advisors LP (2.87%), State Street Corp (2.69%), Geode Capital Management LLC (1.36%), JPMorgan Chase & Co. (1.15%) and American Century Companies Inc. (0.94%). Insiders that own company stock include Hanlin Gao, Jian Xie, John C Bolger, Paul Kim and X Cycle LP Tcv. View institutional ownership trends. How do I buy shares of Fulgent Genetics? Shares of FLGT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Fulgent Genetics' stock price today? One share of FLGT stock can currently be purchased for approximately $38.04. How much money does Fulgent Genetics make? Fulgent Genetics (NASDAQ:FLGT) has a market capitalization of $1.13 billion and generates $618.97 million in revenue each year. The company earns $143.40 million in net income (profit) each year or ($0.89) on an earnings per share basis. How many employees does Fulgent Genetics have? The company employs 1,012 workers across the globe. Does Fulgent Genetics have any subsidiaries? The following companies are subsidiares of Fulgent Genetics: CSI, Cytometry Specialists Inc., FF Gene Biotech, Fulgent Investment Development Limited, Fulgent Therapeutics LLC, and Inform Diagnostics.Read More How can I contact Fulgent Genetics? Fulgent Genetics' mailing address is 4978 SANTA ANITA AVENUE, TEMPLE CITY CA, 91780. The official website for the company is www.fulgentgenetics.com. The company can be reached via phone at (626) 350-0537, via email at nborsje@blueshirtgroup.com, or via fax at 626-454-1667. This page (NASDAQ:FLGT) was last updated on 6/10/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Fulgent Genetics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.